Kornimate/medical-research-clean huggingface dataset:
evaluation of the french version of screening questionnaires for autism and asperger syndrome: aq, eq and sq

Conditions: Asperger Syndrome; Autism

Summary: autism is considered as an invading disorder of the development. asperger syndrome (as) is a particular form of autism and is difficult to diagnose. the autism spectrum quotient (aq) has been developed in order to measure the degree of autistic traits in autistic adolescent with normal intelligence (baron-cohen et al. 2001, 2006). aq comprises 50 questions, with 5 groups of 10 questions assessing imagination, social skills, attention switching, attention to detail and communication skills. each of these items scores 1 point if the respondent records abnormal or autistic like behaviour. the minimum score on the aq is 0 and the maximum 50. the principal objective of this study is to evaluate the accuracy of the french version of autism spectrum quotient questionnaire. secondary objectives are to: evaluate if eq and sq can distinguish adolescents without psychiatric syndromes from those with classical autism or as. evaluate if aq, eq and sq can distinguish adolescents with psychiatric disorders from autistic adolescents. define the threshold of positivity for the 3 questionnaires.

4 groups of participants will be screened with the questionnaires: group 1: 50 adolescents with as or high functioning autism (hfs) diagnosed by psychiatrists using established criteria and with an iq \>85. group 2: 50 adolescents with as or classical autism diagnosed by psychiatrists using established criteria 70\<iq\<84. group 3: 50 adolescents with psychiatric disorders. group 4: sample of 50 healthy adolescents selected randomly from 200. the questionnaires are given to the parents of adolescents during the first meeting. parents are invited to send them back to the clinical investigation centre of lyon (france). multicentre study: 8 clinical centres and 18 paediatricians

Eligibility criteria:
inclusion criteria: group 1 (as/hfa) and 2 (as/classic autism) : * boys and girls aged 12 to 18 * patients with autism or asperger syndrome according to the diagnostic criteria (icd 10) * patients receiving education in an ordinary school * iq\>70 group 3 (adolescents with psychiatric disorders): * boys and girls aged 12 to 18 * patients hospitalized on a psychiatric ward or at a psychiatrics patient visit or psychiatric consultation wit hout autistic syndrome * patients receiving education in an ordinary school when not in hospital group 4 (adolescent without psychiatric syndrome): * boys and girls aged 12 to 18 * patients receiving education in an ordinary school exclusion criteria: for all groups : * problem with language or comprehension * participants who have not given their consent

Keywords: asperger syndrom autism quotient french version screening diagnostic test accuracy
a pharmacovigilance study for adimflu-s (a/h1n1) influenza vaccine in pregnant women

Conditions: Adverse Drug Reactions

Summary: this was a retrospective cohort study of pregnant women who had received the adimflu-s (a/h1n1) influenza vaccine during gestation period. eligibility into the study was confirmed by chart review. if subject meets the eligibility criteria during the study period, data from the medical chart were extracted retrospectively from the date of vaccination and the infant (s) health status were followed until 8 weeks after the delivery.the unexposed cohort included pregnant women who did not receive any influenza vaccine during pregnancy. within each participated study center, women who were gestation after april 2009 were randomly selected according to maternal age matching. the pregnancy outcome, including the status of delivery, abortion and gestational age, were extracted retrospectively by chart review.


Eligibility criteria:
inclusion criteria: exposed cohort: * the woman received adimflu-s (a/h1n1) vaccination between 2009/10 and 2010/02.l * the woman was pregnant at the time of vaccination. unexposed cohort: * the woman was gestation after april 2009. exclusion criteria: exposed cohort: * received any other h1n1 vaccination, e.g., focetria. unexposed cohort: * the woman received any influenza vaccine during gestation period.

Keywords: incidence nature seriousness adrs vaccination
european registry of patients with infantile-onset spinal muscular atrophy

Conditions: Spinal Muscular Atrophy

Summary: io-sma-registry is a prospective, longitudinal and observational study which objective is to collect prospectively information on longevity, psychomotor development and respiratory function of patients with infantile-onset spinal muscular atrophy.


Eligibility criteria:
inclusion criteria: * spinal muscular atrophy diagnosed in childhood (before 18 months) and genetically confirmed. * for patients with sma type 1: never acquired independent sitting position (more than 30 seconds, without hand support or any external support) * for patients with sma type 2 or 3: patient treated with a market approved treatment for sma or with a treatment in an expanded access program * any age * patients over 18 years of age or parent(s)/legal guardian(s) of patients \< 18 years of age not opposed to data collection for research purposes exclusion criteria: * none

Keywords: sma spinal muscular atrophy neuromuscular disease spinraza
exploration of circulating ve-cadherin in metastatic colorectal adenocarcinoma patients treated with bevacizumab

Conditions: Colorectal Cancer; Metastasis

Summary: it is a prospective, non-randomized, monocentric study. the purpose of the study is to assess the predictive value of ve-cadherin on the objective tumor response. biological factors will be correlated to clinical outcome measures. 100 patients treated with bevacizumab for a metastatic colorectal adenocarcinoma will be enrolled. patients will be followed every 10 weeks until progression in spite of bevacizumab or until they stop bevacizumab because of toxicity. bevacizumab will be administered according to investigators appreciation. blood samples will be collected at enrollment, at second bevacizumab's administration and every 10 weeks until progression, or until patients stop bevacizumab because of toxicity or until one year at most in case that patients still receive bevacizumab.


Eligibility criteria:
inclusion criteria: * patient with a metastatic colorectal cancer proved histologically and treated with bevacizumab in first line. * at least one extra-osseous, non-irradiated, measurable site (\>= 10 mm with spiral ct). * no prior radiotherapy treatment unless treatment is over for at least 4 weeks. * adult patients. * ps \<= 2. * life expectancy greater than 3 months. * mandatory affiliation with a healthy security insurance. * signed written informed consent. exclusion criteria: * prior chemotherapy for the metastatic cancer. * prior bevacizumab treatment. * other current cancer or previous cancer detected in the last 5 years that can be linked to the current disease. * patient deprived of freedom. * pregnant or lactating women.
clinical study of the safety and performance of the miami innfocus drainage implant to relieve glaucoma symptoms

Conditions: Glaucoma

Summary: assess the safety and performance of the miami innfocus drainage implant in patients suffering from glaucoma that is inadequately controlled on tolerated medical therapy with intraocular pressure greater than or equal to 18 mm hg and less than or equal to 40 mm hg.

unicentric, non-randomized, single arm safety and performance study which will be conducted in accordance with the applicable parts of cfr 21 and standard en-iso 14155 i \& ii: 2003 on clinical investigations with medical devices on human subjects and recommendations guiding physicians in biomedical research involving human subjects adopted by the 18th world medical assembly, helsinki, finland, 1964 and later revisions

Eligibility criteria:
inclusion criteria: * male or female, age 18 to 85 years, inclusive * glaucoma that is inadequately controlled on tolerated medical therapy with intraocular pressure greater than or equal to 18 mm hg and less than or equal to 40 mm hg. * patient must have signed informed consent form exclusion criteria: * unwilling or unable to give informed consent or unable to return for scheduled protocol visits * pregnant or nursing women * no light perception * active iris neovascularization or active proliferative retinopathy * iridocorneal endothelial syndrome * epithelial or fibrous downgrowth * aphakia (without pseudophakia) * vitreous in anterior chamber for which a vitrectomy is anticipated * chronic or recurrent uveitis * severe posterior blepharitis * unwilling to discontinue contact lens use after surgery * previous ophthalmic surgery, excluding uncomplicated phacoemulsification (cataract) surgery or corneal refractive surgery * need for glaucoma surgery combined with other ocular procedures other than cataract surgery (i.e., penetrating keratoplasty or retinal surgery) or anticipated need for additional ocular surgery * known allergy to mitomycin c (mmc) drug.

Keywords: midi arrow glaucoma drainage device gdd innfocus glaucoma treatment
observational study of novopen echo® on safety and treatment satisfaction in children and adolescents with type 1 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1; Delivery Systems

Summary: this study is conducted in asia, europe and north america. the aim of this observational study is to evaluate the safety of novopen echo® by collecting safety information (incidence of technical complaints related to adverse reactions). study duration: 12-18 weeks.


Eligibility criteria:
inclusion criteria: * children/adolescents with type 1 diabetes mellitus * after the participating physician's decision has been made to initiate treatment with novopen echo®, any patient who meets all the inclusion criteria and does not meet any of the exclusion criteria, is eligible to participate * use of insulin pen or syringes for at least 12 months exclusion criteria: * insulin pump or insuflon® users * any disease or condition in children/adolescents which might interfere with the study at the individual physician's discretion
cap-assisted sigmoidoscopy - influence on pain, duration and rate of success

Conditions: Pain

Summary: the purpose of this study is to investigate the attachment of a transparent hood ("cap") on the sigmoidoscope. the investigators hypothesis is that this will reduce pain, reduce investigation time, and increases the success rate of the sigmoidoscopy. the study focus on the less-experienced endoscopist.

the investigators randomize study subject to sigmoidoscopy +/- the attachment of the cap. using a 100mm vas scale the investigators record pain when the sigmoidoscopy reaches its intubation end-point (60cm from anus). the investigators also register the time spent to this point and the rate of examinations not achieving this endpoint.

Eligibility criteria:
inclusion criteria: * planned to undergo sigmoidoscopy * informed consent exclusion criteria: * use of iv medication for pain and/or anxiety immediately before the endoscopy * lack of indication for a full sigmoidoscopy (eg just need to investigate the rectum) * lack or improper administration of standard bowel preparation

Keywords: sigmoidoscopy with or without cap pain during sigmoidoscopy sigmoidoscopy and time
pharmacotherapy for hiv infected patients with alcohol problems

Conditions: HIV Infection; Heavy Alcoholic Consumption; HIV Infections

Summary: this is a randomized double blind clinical trial to test the effect of naltrexone on hiv infected heavy drinkers. the study will select 40 hiv positive patients who meet criteria for heavy drinking. treatments include naltrexone (25-100mg)and placebo. patients will be treated, followed up, and assessed for a duration of 12 weeks. the investigators associated hypotheses hypothesis 1: naltrexone will reduce the frequency of heavy drinking. hypothesis 2: naltrexone will lead to maintenance or improvement in cd4 lymphocyte count and decreased hiv rna levels. hypothesis 3: naltrexone will lead to a reduction in sexual risk behaviors. hypothesis 4: naltrexone will lead to improved adherence to haart. hypothesis 5 (exploratory): naltrexone will be well-tolerated with minimal side effects and patients will exhibit good treatment retention.


Eligibility criteria:
inclusion criteria: 1. be hiv-positive. 2. report heavy drinking 4 or more times in the past 4 weeks. heavy drinking is defined as 4 or more drinks for women and 5 or more drinks for men on any occasion. 3. not be abstinent from alcohol for greater than 30 days. 4. be at least 18 years old. 5. be able to understand english and provide informed consent exclusion criteria: 1. be psychotic or severely psychiatrically disabled. 2. have medical conditions that would preclude completing or be of harm during the course of the study. 3. have laboratory or clinical evidence of significant liver dysfunction (alanine aminotransferase (alt) or aspartate aminotransferase (ast) greater than 3 times the upper limit of the normal range) or cirrhosis. 4. have a known contraindication to naltrexone therapy (e.g. taking opioid medication for pain). 5. be pregnant, nursing or unable to use an effective method of birth control (women). 6. subjects who are taking or use narcotics will not be included because naltrexone will precipitate withdrawal.

Keywords: hiv alcohol naltrexone treatment experienced
establish and apply the evaluation system of ultrasonic integrated technology for prevention and treatment of acute kidney injury

Conditions: Acute Kidney Injury

Summary: establish an integrated evaluation system of ultrasound technology for the prognosis of acute kidney injury, and in order to achieve non-invasive, reliable early diagnosis "gold standard". set up collabration with the expert in national cheng kung university medical center of taiwan who did a lot of excellent work in basic research of prevention the progression of acut kidney injury. study the experience about prevention progression of kidney disease in clinical and basic field. establish cooperation with the professional in hong kong university of science and technology. to set up the system of natural products research and assess the astragalus medicinal value.


Eligibility criteria:
inclusion criteria: * subjects must satisfy the following criteria to be enrolled in the study: 1. clinical diagnosis of acute or chronic kidney injury 2. male or female, aged 18-80 years old 3. signed informed consent 4. patients can breathe in, breathe out and hold their breathe with ease, communication without difficulty. exclusion criteria: * potential subjects who meet any of the following criteria will be excluded from participating in the study: 1. refuse to sign informed consent 2. allergy to micro bubble hexafluoride drug 3. patients with cardiopulmonary insufficiency, pleural effusion, pulmonary infections 4. patients with asthma, chronic bronchitis 5. patients with pregnancy 6. patients can't cooperate or have a difficulty in breathing in, breathing out or holding their breathe 7. patients beening diagnosed with end-stage kidney disease.

Keywords: acute kidney injury ultrasound technology
arthroscopic assisted volar, dorsal or combined capsulodesis in scapholunate ligament injury.

Conditions: Scapholunate Interosseous Ligament Injury; SLLI

Summary: the aim of this case series study is to test the efficacy of arthroscopic assisted volar, dorsal or combined scapholunate capsulodesis in the management of scapholunate ligament injuries.

the aim of this case series study is to test the efficacy of arthroscopic assisted volar, dorsal or combined scapholunate capsulodesis in the management of scapholunate ligament injuries. all patients will be assessed preoperatively by careful history taking , full general and local examination and radiological evaluation using wrist plain x-rays (standard pa, clenched-fist pa , pa in ulnar deviation , lateral projection in neutral ,flexion and extension ) and wrist magnetic resonance imaging.an informed written consent was taken before any surgery. the procedure starts with a standard radiocarpal and then midcarpal arthroscopy. during the arthroscopic examination ,several factors are assessed, including the location of the slil injury (volar, membranous, dorsal, or complete), the condition of the cartilage, the reducibility of the carpus, and other associated pathologies like tfcc injury. classification is done using geissler classification, garcia elias classification and ewas classification.volar capsulodesis using hayman lui et al or del pinal et al method and/or dorsal capsulodesis using original mathoulin technique or combined capsulodesis were done.

Eligibility criteria:
inclusion criteria: * sex: both sexes. * age: above 18 years * lesion: subacute or chronic scapholunate ligament injury * partial and complete slil tears exclusion criteria: * acute scapholunate ligament injury * irreducible carpal malalignment * posttraumatic arthritis * associated fractures that could affect the functional outcome
clinical evaluation of acupuncture in treating glaucoma

Conditions: Glaucoma; Acupuncture

Summary: the present study predicts that acupuncture or electroacupuncture can reduce intraocular pressure and also can improve quality of life in patients with glaucoma.

glaucoma is a syndrome, and that is results from intraocular pressure increases cause visual field narrow and blindness. the incidence of adult blindness induced by glaucoma is second in the ophthalmologic disease in the world. many studies report that both blood circulation in the eye surroundings and intraocular pressure increase play an important role in glaucoma. several studies show that acupuncture can modulate intraocular pressure and improve activity of central visual acuity and also increase blood flow of eye fundus. jingming (bl1) can communicate yi and yang, and nourish and clear eyes, qiuhou (ex-hn7) can transport qi and activate blood, and freely flowing meridian and clear eyes. therefore, the purpose of the present study was to investigate the therapeutic effect of acupuncture at jinming and qiuhou on intraocular pressure in patients with glaucoma. the study designed as a single-blinded, randomized, controlled clinical trial, a total of45 patients with glaucoma divided into three groups, each group was15 subjects as follows: 1) sham group, using the seeds of wang-bu-liu-xing applied on the surface of jinming and qiuhou acupoints, one times/day, and each time was 20 min, twice/week for 2 weeks; 2) acupuncture group, the methods were identical to the sham group, but used acupuncture applied to qingming and qiuhou with der-qi; 3) electroacupuncture group, the methods were identical to acupuncture, but the needles of qinming and qiuhou connected to the electroacupuncture machine after der-qi, the frequencies of stimulus were 6 hz, the intensity of stimulus was minimal visible muscle twitch. primary outcome measure was the changes of intraocular pressure, and the second outcome measure was the score changes of whoqol-ref (taiwan version). the present study predicts that acupuncture or electroacupuncture can reduce intraocular pressure and also can improve quality of life in patients with glaucoma.

Eligibility criteria:
inclusion criteria: 1. glaucoma for at least three months 2. do not use ocular hypotensive drugs or use only one ocular hypotensive drug. 3. it is over 20 years old. 4. men and women are informal. 5. there is no evidence other than glaucoma that shows other eye diseases. 6. be aware and fill out the consent form yourself. exclusion criteria: 1. combines other chronic diseases, taking multiple medications such as high blood pressure, diabetes, etc. 2. those who have had glaucoma surgery. 3. those who had undergone myopia laser surgery. 4. can not accept acupuncture points stimulators. 5. allergic to acupuncture needles. 6. has a mental illness or is unable to cooperate with the researcher. 7. do not sign consent
a study of technology to improve glucose control in participants with type 1 diabetes

Conditions: Diabetes Mellitus, Type 1

Summary: the main purpose of this study is to determine whether combining meal, glucose, and insulin data in a web-based system will improve management of type 1 diabetes (t1d). no study drug will be given. the study will last about 18 weeks.


Eligibility criteria:
inclusion criteria: * t1d by clinical diagnosis for \> 3 years * insulin pump use \> 3 months: must use one of the following pump types: animas ping and vibe, insulet omnipod, medtronic 523/723 and 530g, tandem t:slim and t:flex * continuous glucose monitor (cgm) \> 3 months and current use of dexcom g5 at least 6 out of 7 days per week * hba1c 7.0-9.5% * must have iphone (meal-tagging app has been built on ios) * personal computer for uploading of pump and cgm devices * willingness to follow study protocol including tagging food data * comfort speaking, reading, and writing english exclusion criteria: * individuals currently using a hybrid closed-loop system (e.g., medtronic 670g) * individuals planning to follow a specific diet plan for weight loss * inability to consume "common meals" * gastroparesis; * eating disorder * evidence of missed insulin meal-time insulin boluses on pump download * use of medications that can affect blood glucose levels (such as sglt inhibitors, steroid, beta agonists) * use of medications that affect gastric emptying (such as glp agonists, pramlinitide) * alcohol abuse * pre-conception, pregnancy, or lactation
ex-vivo sentinel lymph node in stage i-ii colon cancer: kappa analysis with immunochemistry and molecular biology

Conditions: Colon Cancer; Lymph Node; Sentinel Node

Summary: unmask trial aims to evaluate the kappa concordance between immunochemistry and molecular biology to detecting cancer cells in sentinel lymph node in patients undergoing colectomy for non metastatic colon cancer.


Eligibility criteria:
inclusion criteria: * colectomy for non metastatic colon cancer exclusion criteria: * tumor t4 * no medical insurance * pregnant woman * psychiatric disorders

Keywords: colon cancer sentinel node
short-term blinatumomab as a bridge therapy for allo-hsct in low burden b-all

Conditions: Leukemia, Lymphoid

Summary: the goal of this single-arm, prospective study is to test in low-burden b-cell lymphoblastic leukemia (b-all) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-hsct). the main question it aims to answer is: • the efficacy and safety of short-term blinatumomab as a bridging therapy to allo-hsct in patients with low-burden b-all. participants will take intravenous blinatumomab prior to allo-hsct with an initial dosage of 8 μg/day. the dosage gradually escalated to 28 μg/day and continued for 5 to 10 days. dexamethasone 20mg was administered 1 hour before the onset of blinatumomab infusion.


Eligibility criteria:
inclusion criteria: 1. patients diagnosed with b-all; 2. patients with age ≥ 16 years; 3. availability of both pre- and post-transplantation disease status records. exclusion criteria: 1. administration of blinatumomab therapy for more than 14 days; 2. patients with leukemia burden ≥ 10% before initiation of treatment; 3. patients with severe organ dysfunctions before treatment, including myocardial infarction, chronic heart failure, decompensated liver dysfunction, renal dysfunction, or gastrointestinal dysfunction; 4. patients with central nervous system leukemia.